ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on X

Kidney Week

Abstract: PUB744

Monoclonal IgG4/2-Kappa Deposition Following Eculizumab Therapy for Recurrent Atypical Hemolytic Uremic Syndrome (aHUS) in Kidney Transplantation

Session Information

Category: Transplantation

  • 1702 Transplantation: Clinical and Translational


  • Singh, Priyamvada, Boston University Medical Center, Boston, Massachusetts, United States
  • Chen, Hui, BMC, Boston, Massachusetts, United States
  • Gordon, Craig E., None, Natick, Massachusetts, United States
  • Sloan, John M, Boston MEdical Center, Boston, Massachusetts, United States
  • Quillen, Karen, Boston University Medical Center, Boston, Massachusetts, United States
  • Chitalia, Vipul C., Boston University School of Medicine, Boston, Massachusetts, United States
  • Gautam, Amitabh, Boston Medical Center, Boston, Massachusetts, United States
  • Henderson, Joel M., Boston University Medical Center, Boston, Massachusetts, United States
  • Francis, Jean M., Boston University Medical Center, Boston, Massachusetts, United States

Eculizumab is emerging as a promising therapy for aHUS. We present a patient with rapid resolution of recurrent aHUS after kidney transplantation following eculizumab therapy but with evidence of monoclonal IgG4/2-kappa deposition on repeat kidney biopsy


A 22-year-old male with CKD stage 5 of unknown etiology underwent preemptive living related kidney transplantation from his sister. His post-operative course was complicated by thrombocytopenia on day 3 after transplant (nadir platelet count: 36k/ul) and delayed graft function. Testing revealed elevated LDH (673 U/L, normal 171-308), low haptoglobin (<7 mg/dL, normal 44-184), and schistocytosis on peripheral blood smear. Eculizumab was initiated for possible recurrent aHUS on day 3 post-transplant. Kidney biopsy performed on day 5 post-transplant following a recovery of thrombocytopenia confirmed the diagnosis of acute thrombotic microangiopathy (TMA). Hematological parameters improved rapidly following treatment but the renal function did not improve as expected. A repeat kidney biopsy performed after 5 doses of eculizumab demonstrated complete resolution of TMA features on a background of essentially normal renal parenchyma. Interestingly, immunofluorescence microscopy revealed monoclonal staining for IgG4/2-kappa in glomeruli, vasculature, and focally in tubular basement membranes. The deposits suggest eculizumab deposition because eculizumab is a hybrid monoclonal immunoglobulin comprised of IgG4/2-kappa chains. IgG4/2-kappa deposits are rare pathological findings seen following eculizumab therapy.


Early identification and treatment of recurrent TMA after transplantation require a high clinical suspicion but result in improved graft function and patient outcome. IgG4/2-kappa deposits are a rare pathological finding following effective eculizumab therapy but the long-term effects of these deposits on renal function remain unknown.